There's been a lot of discussion lately about the need to control rising health care costs, and the role of new medicines and medical technology. Nowhere has this discussion been sharper than in the area of oncology. At PhRMA, we’ve been joining in many of these discussions, working with other stakeholders to identify solutions to sustain continued progress and support efficient delivery of optimal patient care.
Most Recent Posts
Within the medical community there is so much truth to the saying, “knowledge is power.” Whether it’s sharing information about a new medicine in development that could save a patient’s life, or sharing resources and ideas to change a patient’s life, it is essential that patients, doctors, and other members of the health care ecosystem stay well informed and disseminate their knowledge.
It’s no coincidence that February is American Heart Month and host to Valentine’s Day, and as a result, there is no better time to focus on your heart.
In last week’s #RarePOV tweetchat, leading rare disease advocacy organizations and individual patient advocates came together to share resources and plans for the upcoming international Rare Disease Day.
With the tragic news of Philip Seymour Hoffman’s death, the national conversation around addiction has gained a new focal point. Though Hoffman died from a heroin overdose, his death has intensified an ongoing discussion about the abuse and misuse of painkillers and other medicines.
The importance of protecting intellectual property cannot be overstated. For the biopharmaceutical industry, ensuring our ability to innovate is essential for continued R&D to help patients live longer, healthier lives.
Every day there is a war to wage against the world’s most devastating diseases. It is a fight we must win to make the world a safer, healthier place for our patients, and this week we discussed some of the battles currently underway.
As highlighted in an earlier Catalyst post, PhRMA is partnering with Genetic Alliance on an exciting project to enhance patient engagement in the Food and Drug Administration’s (FDA) Patient-Focused Drug Development initiative. Genetic Alliance recently launched the first pilot program, partnering with four trusted organizations serving the sickle cell community.
A new study examines the economic impact of India’s current approach to intellectual property rights as it affects pharmaceutical products and Foreign Direct Investment (FDI). The study from Sonecon by Robert Shapiro and Aparna Mathur titled “How India Can Attract More Foreign Direct Invest Investment, Create Jobs, and Increase GDP: The Benefits of Respecting the Intellectual Property Rights of Foreig
Today, on World Cancer Day, we celebrate the remarkable progress that’s been made in the fight against a devastating disease that has touched all of us.
A groundbreaking new partnership was announced earlier today by the National Institutes of Health (NIH).
The Washington Legal Foundation recently convened an enlightening expert roundtable discussion about the impact of late 2012's decision in U.S. vs. Caronia.
What does working in a lab have in common with flying an airplane? A great deal according to the next researcher highlighted in our “I am Research, Progress, Hope” series, Dowdy Jackson, head of the Antibody Drug Conjugate (ADC) Biology group at Agensys, an affiliate of Astellas.
As of January 1, researchers are now able to submit proposals to receive access to patient level data, protocols, and clinical study reports for new medicines approved in the U.S and EU after January 1, 2014. The biopharmaceutical sector’s commitment to data sharing provides new avenues for the scientific community and patients to benefit from clinical research, while maintaining patient privacy, the integrity of national regulators, and incentives for companies to make long-term investments in biomedical research.
Dr. Robert Freeman, Professor of Pharmacy Administration (health services research) in the Department of Pharmacy Practice & Administration at the University of Maryland Eastern Shore School of Pharmacy, comments on the recently released paper from University College London School of Pharmacy on patient’s needs and intellectual property in middle income countries.